FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324252401> ?p ?o ?g. }

• W2324252401 endingPage "A154" @default.
• W2324252401 startingPage "A153" @default.
• W2324252401 abstract "<h3>Objective</h3> To observe the effects of tongxinluo capsule on platelet activity and function of vascular endothelium as well as prognosis at different stage in patients with acute coronary syndrome after PCI. <h3>Methods</h3> One hundred and sixty patients with acute coronary syndrome were randomly divided into tongxinluo (TXL) group (80 patients) and conventional treatment group (80 patients). Another 50 healthy people as control group. We examined the patient9s blood CD62p, CD63, glucose protein (GP) αb/βa and endothelium 1 (ET-1), von Willebrand factor (vWF), nitric oxide (NO) levels, and flow- mediated dilatation (FMD) in brachial artery from before treatment and the second day after the treatment of PCI in both group. Then the patients in TXL group received TXL treatment for 6 months (four tablet tid), and compared the results with conventional treatment group. <h3>Results</h3> The ACS patient9 s blood CD62p, CD63, GPαb/βa, vWF and ET-1 levels increased significantly (all p<0.01), NO and FMD decreased significantly (p<0.01) when compared with healthy control group. The ACS patient9s plasma levels of vWF increased significantly (p<0.05), CD62p, CD63, GPαb/βa while FMD decreased significantly (p<0.05) after PCI group compared with before PCI group. In both TXL treatment group and convention treatment group, the patient9s plasma levels of CD62p, CD63, GPαb/βa, vWF and ET-1 decreased significantly (p<0.05, p<0.01), FMD increased significantly (p<0.05, p<0.01) compared with pre-treatment group. There were significant different of all parameters above between TXL group and conventional treatment group (p<0.01, p<0.05). In addition, the parameter above showed significant different after treatment of 6 months than 2 months (p<0.01, p<0.05). There were two cases of sudden death, seven cases of recurrent angina, three cases of ventricular tachycardiac (VT)/ventricular fibrillation (VF) in conventional treatment group after 6 months, while there were one case of recurrent angina, one case of heart failure, without VT/VF and sudden death occurred in the TXL treatment group after 6 months. <h3>Conclusions</h3> TXL can inhibit the patient9s platelet activity and protect the vascular endothelium function as well as improve the prognosis after the treatment of PCI." @default.
• W2324252401 created "2016-06-24" @default.
• W2324252401 creator A5010990613 @default.
• W2324252401 creator A5051526729 @default.
• W2324252401 creator A5079974540 @default.
• W2324252401 creator A5088498311 @default.
• W2324252401 date "2011-10-01" @default.
• W2324252401 modified "2023-09-26" @default.
• W2324252401 title "The effects of tongxinluo capsule on platelet activity and vascular endothelium function as well as prognosis at different stage in patients with acute coronary syndrome undergoing percutaneous coronary intervention" @default.
• W2324252401 doi "https://doi.org/10.1136/heartjnl-2011-300867.447" @default.
• W2324252401 hasPublicationYear "2011" @default.
• W2324252401 type Work @default.
• W2324252401 sameAs 2324252401 @default.
• W2324252401 citedByCount "0" @default.
• W2324252401 crossrefType "journal-article" @default.
• W2324252401 hasAuthorship W2324252401A5010990613 @default.
• W2324252401 hasAuthorship W2324252401A5051526729 @default.
• W2324252401 hasAuthorship W2324252401A5079974540 @default.
• W2324252401 hasAuthorship W2324252401A5088498311 @default.
• W2324252401 hasBestOaLocation W23242524011 @default.
• W2324252401 hasConcept C126322002 @default.
• W2324252401 hasConcept C164705383 @default.
• W2324252401 hasConcept C2776992346 @default.
• W2324252401 hasConcept C2777604165 @default.
• W2324252401 hasConcept C2777698277 @default.
• W2324252401 hasConcept C2779394231 @default.
• W2324252401 hasConcept C2780400711 @default.
• W2324252401 hasConcept C3018697912 @default.
• W2324252401 hasConcept C45393284 @default.
• W2324252401 hasConcept C500558357 @default.
• W2324252401 hasConcept C71924100 @default.
• W2324252401 hasConcept C84393581 @default.
• W2324252401 hasConcept C89560881 @default.
• W2324252401 hasConcept C90924648 @default.
• W2324252401 hasConceptScore W2324252401C126322002 @default.
• W2324252401 hasConceptScore W2324252401C164705383 @default.
• W2324252401 hasConceptScore W2324252401C2776992346 @default.
• W2324252401 hasConceptScore W2324252401C2777604165 @default.
• W2324252401 hasConceptScore W2324252401C2777698277 @default.
• W2324252401 hasConceptScore W2324252401C2779394231 @default.
• W2324252401 hasConceptScore W2324252401C2780400711 @default.
• W2324252401 hasConceptScore W2324252401C3018697912 @default.
• W2324252401 hasConceptScore W2324252401C45393284 @default.
• W2324252401 hasConceptScore W2324252401C500558357 @default.
• W2324252401 hasConceptScore W2324252401C71924100 @default.
• W2324252401 hasConceptScore W2324252401C84393581 @default.
• W2324252401 hasConceptScore W2324252401C89560881 @default.
• W2324252401 hasConceptScore W2324252401C90924648 @default.
• W2324252401 hasIssue "Suppl 3" @default.
• W2324252401 hasLocation W23242524011 @default.
• W2324252401 hasOpenAccess W2324252401 @default.
• W2324252401 hasPrimaryLocation W23242524011 @default.
• W2324252401 hasRelatedWork W2066237471 @default.
• W2324252401 hasRelatedWork W2085947382 @default.
• W2324252401 hasRelatedWork W2129387994 @default.
• W2324252401 hasRelatedWork W2171240439 @default.
• W2324252401 hasRelatedWork W2324252401 @default.
• W2324252401 hasRelatedWork W2365351346 @default.
• W2324252401 hasRelatedWork W2384842144 @default.
• W2324252401 hasRelatedWork W2388706577 @default.
• W2324252401 hasRelatedWork W2919572950 @default.
• W2324252401 hasRelatedWork W2978761503 @default.
• W2324252401 hasVolume "97" @default.
• W2324252401 isParatext "false" @default.
• W2324252401 isRetracted "false" @default.
• W2324252401 magId "2324252401" @default.
• W2324252401 workType "article" @default.